ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.
Abstract
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [7]
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Based on the data collected during the parent clinical trials and other studies, LDL-C levels typically reach nadir after 4 weeks of receiving evinacumab infusion and remain generally stable at week 6.9”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Cited by
Items 301–329 of 329
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Finalement, jusqu’où faut-il baisser le LDL-cholestérol et comment ?
Béliard, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.011 · Cited by 1
Neue Therapieansätze in der LDL-Cholesterin-Absenkung?
Schettler, V. J. J. (2021) · Dialyse aktuell · doi:10.1055/a-1401-3142
Efecto de la inhibición de la proteína símil angiopoyetina tipo 3 (ANGPTL3)
Elikir, G. D. (2021) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/revhospitalbaires.v41i3.108
Anderson, J. L. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192996734
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1412728/v1
Farnier, M. (2021) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(21)45461-9
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1420016/v2
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1420016/v3
[Advances in diagnosis and treatment of familial hypercholesterolemia].
Zheng, H., Jiang, S., & Li, L. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.01.22
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560.sa2
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Evinacumab—a treatment for homozygous familial hypercholesterolemia
Basaria, A. A. A., Fatima, I., & Raufi, N. K. (2023) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000254
“ANGPTL3 is expressed primarily in the liver and acts as an endogenous inhibitor of lipoprotein lipase and endothelial lipase which are responsible, in part, for metabolizing triglycerides and high-density lipoprotein cholesterol, respectively([13]) In phase 2, an open-label, proof-of-concept study involving 9 patients…”
BackgroundPlaying the genetic lottery: an interview with Kiran Musunuru
Musunuru, K. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050508
“However, we found that ANGPTL3 regulates LDL cholesterol independently of the LDL receptor, which means that you can target this gene in patients with very high cholesterol who don ’ t have any LDL receptor (Gaudet et al., 2017).”
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Larouche, M., & Gaudet, D. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.009
Self-citationKhalil, Y. A. (2021) · theses.fr (ABES) · doi:10.70675/1964fe3fz37bfz493azb98czc7caecac12cf
Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review
Rodrigues, L. D. S., & Bertanha, M. (2025) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2025.0005
Trinh, Y. W. I., Panteloglou, G., Voloviceva, E., Lone, M. A., Bernhard, S., Schlumpf, E., Frey, K., Rohrer, L., Gonzales, M. J. M., Lutz, T. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.30.679508
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Michaeli, D. T. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00035637
Lauzière, A. (2023) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/27194
Schonck, W. A. M., Crosti, C., Marchesin, A., Gallo, A., Kayıkçıoğlu, M., Banach, M., Cuchel, M., Jones, R. E., Kainth, P., Catapano, A. L., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i3.115
“ANGPTL3 inhibits lipoprotein lipase, an enzyme involved in the hydrolysis and clearance of triglyceride-rich lipoproteins [6, 7].”
Self-citationL’hypercholestérolémie familiale homozygote : une urgence diagnostique et thérapeutique
Béliard, S., Chauvet, M., & Moulin, P. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.01.006
Volpi, L., Spira, D., Mai, K., Demuth, I., Steinhagen‐Thiessen, E., Kassner, U., & Bobbert, T. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.004 · Cited by 2
“19-21 In the pivotal Phase 3 ELIPSE HoFH clinical trial, evinacumab, compared to placebo, reduced LDL-C levels by 49% from baseline in HoFH patients despite concurrently using other lipid-lowering therapies (LLTs) such as statins and PCSK9 inhibitors.”
Robert, J. (2026) · Cells · doi:10.3390/cells15131191
“ANGPTL inhibitors are in clinical development for the treatment of severe hypertriglyceridemia and familial hypercholesterolemia [110,111].”
Bajaj, A., McGuire, M., Shugg, S., Godin, R., & Underberg, J. A. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101790
“…studies in healthy volunteers and in adult, adolescent, and pediatric participants with HoFH followed, as well as real-world studies carried out since regulatory approval, all of which have demonstrated the efficacy of evinacumab in reducing LDL-C alongside a well-tolerated safety profile [22 – 28,”
InfluentialReijman, M. D., Nigmann, C., Kusters, D. M., Planken, R. N., Loewe, C., Verpalen, V. A., Hovingh, G. K., Neyer, M., Draxler-Dworzak, S., Mair, K. S., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048419
“16,17 Subsequent studies in adults and adolescents with HoFH followed patients for up to 4 years after a 24-week course of evinacumab and found that long-term efficacy and safety of evinacumab were sustained irrespective of LDLR genotype, and background LLT, 18,19 a finding recently substantiated…”
Self-citationHu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Metadata
- Authors
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl, N., Yancopoulos, G. D., & Hovingh, G. K.
- Affiliations
- Université de Montréal (CA)
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pennsylvania (US)
- Cedars-Sinai Medical Center (US)
- University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 296-297
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2738009647
- Cited by
- 323
- References
- 5
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 29 · 2023: 23 · 2022: 41 · 2021: 58 · 2020: 62 · 2019: 36 · 2018: 30 · 2017: 4
- FWCI
- 36.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, evinacumab, homozygous familial hypercholesterolemia, LDL cholesterol lowering, monoclonal antibodies, cholesterol absorption inhibition, lipid-lowering therapy
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Antibodies, Monoclonal, Genotype, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Receptors, LDL, Angiopoietins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.